27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- WHO's Technical Advisory Group has recommended the Emergency Use Listing status for Bharat Biotech's COVID-19, Covaxin.
- Read Next: Ocugen Reverses Course From Monday's Massive Surge As COVID-19 Vaccine Partner Faces WHO Setback.
- Ocugen Inc (NASDAQ:OCGN) is the U.S. partner for the India-made vaccine.
- The World Health Organization's panel had last week sought additional clarifications from the firm.
- The Technical Advisory Group had met on October 26 and sought additional details from Bharat Biotech.
- Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.
- Related Link: Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report.
- WHO's approval will open travel channels to several countries that are yet to include Covaxin in their approved list of vaccines.
- Additionally, Covaxin has been granted an extension of shelf life for up to 12 months from the date of manufacture by India's drug regulator.
- Covaxin initially had a shelf life of six months.
- Price Action: OCGN shares are down 4.47% at $14.98 during the market session on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!